Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kazuhiro Shibayama"'
Autor:
Hiroji Uemura, Takefumi Satoh, Hideyasu Tsumura, Gaku Arai, Keiichiro Imanaka, Kazuhiro Shibayama, Koji Fujii, Brendan Rooney, Angela Lopez-Gitlitz, Byron Espina, Carlos Perez-Ruixo, Eric J. Small, Matthew Smith
Publikováno v:
Prostate International, Vol 8, Iss 4, Pp 190-197 (2020)
Background: In the global Phase-3 Selective Prostate Androgen Receptor Targeting with ARN-509 study, apalutamide plus ongoing androgen deprivation therapy (ADT) significantly increased metastasis-free survival (MFS) and improved other clinical outcom
Externí odkaz:
https://doaj.org/article/d97fbd9a51004654a21352bf6702ce26
Autor:
Suneel Mundle, Namphuong Tran, Toshitaka Shin, Kazuhiro Shibayama, Satoshi Fukasawa, Nobuaki Matsubara, Hiroyoshi Suzuki, Noriyuki Ohtake, Sumiko Kitani, Katsuyoshi Hashine, Karim Fizazi
Publikováno v:
Japanese Journal of Clinical Oncology
Background LATITUDE was a randomized, double-blind, international and phase 3 study of abiraterone acetate plus prednisone in patients with high-risk metastatic hormone-naïve prostate cancer. In the first interim analysis of LATITUDE (clinical cutof
Autor:
Shinsuke Iida, Morio Matsumoto, Hiroshi Kosugi, Hiroshi Yamazaki, Kazuhiro Shibayama, Hirohiko Shibayama
Publikováno v:
International journal of hematology. 113(1)
Subcutaneous daratumumab (DARA SC; daratumumab co-formulated with recombinant human hyaluronidase PH20) is administered in ~ 5 min and demonstrates safety and efficacy comparable to intravenous daratumumab, with low infusion-related reaction (IRR) ra
Autor:
Brendan Rooney, Matthew R. Smith, Byron M. Espina, Gaku Arai, Eric J. Small, Angela Lopez-Gitlitz, Takefumi Satoh, Hiroji Uemura, Carlos Perez-Ruixo, Hideyasu Tsumura, Keiichiro Imanaka, Kazuhiro Shibayama, Koji Fujii
Publikováno v:
Prostate International
Prostate International, Vol 8, Iss 4, Pp 190-197 (2020)
Prostate International, Vol 8, Iss 4, Pp 190-197 (2020)
Background In the global Phase-3 Selective Prostate Androgen Receptor Targeting with ARN-509 study, apalutamide plus ongoing androgen deprivation therapy (ADT) significantly increased metastasis-free survival (MFS) and improved other clinical outcome
Autor:
Keisuke Matsuki, Morihito Tokai, Norimasa Takahashi, Sakae Tanaka, Kazuhiro Shibayama, Kazutomo Onishi, Hiroyuki Sugaya
Publikováno v:
Arthroscopy: The Journal of Arthroscopic & Related Surgery. 34:2541-2548
Purpose This retrospective study aimed to report repair integrity and clinical outcomes after arthroscopic suture bridge subscapularis (SSC) tendon repair. Methods The subjects included 101 shoulders subjected to arthroscopic suture bridge repair for
Autor:
Hiroshi Iwaso, Kazuhiro Shibayama
Publikováno v:
Journal of Shoulder and Elbow Surgery. 26:888-894
The Hill-Sachs lesion (HSL) plays a role in recurrent glenohumeral joint instability. Currently, there are no studies based on the form characteristics of HSL. The purposes of this study were to report the HSL form characteristics and to determine wh
Autor:
Kazuhiro Shibayama, Kenshi Suzuki, Hirohiko Shibayama, Hiroyuki Takamatsu, Shinsuke Iida, Hiroshi Yamazaki
Publikováno v:
International journal of hematology. 111(5)
Lenalidomide and dexamethasone (Rd) treatment is common for patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem-cell transplantation. Daratumumab plus Rd (D-Rd) is effective and well tolerated for treating relapsed or
Autor:
Takatoshi Takubo, Masafumi Ikeda, Takuji Okusaka, Kazuhiro Shibayama, Akira Fukutomi, Yoshikazu Kobayashi, Jennifer Gansert
Publikováno v:
Japanese Journal of Clinical Oncology. 44:442-447
Objective Previous Phase 1 studies have shown the acceptable safety profile of ganitumab-a fully human monoclonal antibody to insulin-like growth factor Type 1 receptor-in patients with advanced solid tumors. However, ganitumab 20 mg/kg in combinatio
Autor:
Takatoshi Takubo, Elwyn Loh, Kazuhiro Shibayama, Nozomu Fuse, Junichiro Watanabe, Takayuki Yoshino, Nobuyuki Yamamoto, Satoru Otani, Toshihiko Doi, Atsushi Ohtsu, Narikazu Boku, Haruyasu Murakami
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This study was to investigate the safety and tolerability of ganitumab in Japanese patients with advanced solid tumors. Methods Patients were enrolled into 1 of 3 dose cohorts (6, 12, or 20 mg/kg) of single-agent ganitumab administered intrav
Publikováno v:
Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku. 14:79-88